Chapter 3 Market and Technology Background
- DNA Damage
- Sources of DNA Damage
- DNA Repair Mechanism
- Base Excision Repair and Nucleotide Excision Repair
- Repair of Double-Strand Breaks
- Nucleotide Excision Repair
- Mismatch Repair
- Homologous Recombination (HR)
- Non-Homologous End Joining (NHEJ)
- Alternative End Joining
- Targets for Cancer Therapy
- DNA Damage Response for Cancer Chemotherapy
- Targeting PARP-1
- Targeting APE 1
- Targeting XRCC 1
- Targeting DNA-PKcs
- Targeting Ligases
- Targeting PI-3 kinase
Chapter 4 Market Breakdown by Technology Type
- Poly(ADP-Ribose) Polymerase Inhibitors
- Structure and Function of PARP Inhibitors
- Use of PARP Inhibitors in Treatment
- FDA-approved PARP Inhibitors for Use in Cancer Treatment
- PARP Inhibitors in Clinical Trials
Chapter 5 Market Breakdown by Application
- Ovarian Cancer
- Epidemiology of Ovarian Cancer
- Risk Factors for Ovarian Cancer
- Breast Cancer
- Risk Factors for Breast Cancer
- Signs and Symptoms
- Treatment
- Challenges
- Global Impact
Chapter 6 Market Breakdown by Region
- Market Overview and Discussion
- Rise of DNA Repair Cases by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 7 R&D in the Pharmaceutical Industry
- Healthcare Expenditures
- Continued Emphasis on R&D Activities
- Trends in the Pharmaceutical Industry
- Factors Influencing Spending for R&D
- Trends in R&D Spending and New Drug Development
- R&D Spending
- New Drug Development
- Approvals of New Drugs
- Trends in Recent Drug Spending by Therapeutic Class
- Types of New Drug Development
- Factors Influencing R&D Spending
- Projected Revenues
- Revenues as Funding for R&D
- New Drug Costs in R&D
Chapter 8 DNA Repair Inhibitors on SARS-CoV-2
- Biological Structure of SARS-CoV-2
- Viral Infection Induces DNA Damage
- Federal Funding for the Development of COVID-19 Vaccines
Chapter 9 Company Profiles
- ABBVIE INC.
- AMGEN INC.
- ABBOTT LABORATORIES
- ASTRAZENECA PLC
- BAYER AG
- BRISTOL-MYERS SQUIBB CO.
- ELI LILLY
- F. HOFFMANN-LA ROCHE LTD.
- GILEAD SCIENCES INC.
- GLAXOSMITHKLINE PLC
- JOHNSON & JOHNSON
- MERCK & CO., INC.
- MERCK KGAA
- NOVARTIS AG
- PFIZER INC.
- SANOFI S.A.
List of Tables
Summary Table : Global Market for DNA Repair Drugs, by Type, Through 2026
Table 1 : Global Market for DNA Repair Drugs, by Type, Through 2026
Table 2 : FDA-Approved PARP Inhibitors
Table 3 : Global Market for DNA Repair Drugs, by Application, Through 2026
Table 4 : Global Market for DNA Repair Drugs, by Region, Through 2026
Table 5 : North American Market for DNA Repair Drugs, by Country, Through 2026
Table 6 : European Market for DNA Repair Drugs, by Country, Through 2026
Table 7 : Asia-Pacific Market for DNA Repair Drugs, by Country, Through 2026
Table 8 : Rest of the World Market for DNA Repair Drugs, Through 2026
Table 9 : AbbVie: Oncology Pharmaceutical Revenue, 2018-2020
Table 10 : AbbVie: Oncology Pharmaceutical Products Portfolio
Table 11 : AbbVie: Marketed Products
Table 12 : AbbVie: Key Developments, 2021
Table 13 : Allergan PLC: Marketed Products
Table 14 : Amgen: Oncology Pharmaceutical Products Portfolio
Table 15 : AstraZeneca: Oncology Pharmaceutical Products Portfolio
Table 16 : AstraZeneca: Oncology Pharmaceutical Revenue, 2018-2020
Table 17 : Bayer AG: Marketed Products
Table 18 : Bayer AG: Oncology Pharmaceutical Products Portfolio
Table 19 : Bayer AG: Oncology Pharmaceutical Revenue, 2018-2020
Table 20 : Bristol-Myers Squibb: Oncology Pharmaceutical Products Portfolio
Table 21 : Bristol-Myers Squibb: Oncology Pharmaceutical Revenue, 2018-2020
Table 22 : Eli Lilly and Co.: Marketed Products
Table 23 : Eli Lilly and Co.: Oncology Pharmaceutical Products Portfolio
Table 24 : Eli Lilly and Co.: Oncology Pharmaceutical Revenue, 2018-2020
Table 25 : Roche: Oncology Pharmaceutical Products Portfolio
Table 26 : Roche: Oncology Pharmaceutical Revenue, 2018-2020
Table 27 : Johnson & Johnson: Oncology Pharmaceutical Products Portfolio
Table 28 : Johnson & Johnson: Oncology Pharmaceutical Revenue, 2018-2020
Table 29 : Merck & Co., Inc.: Marketed Products
Table 30 : Merck & Co., Inc.: Oncology Pharmaceutical Products Portfolio
Table 31 : Merck & Co., Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 32 : Merck KGaA: Marketed Products
Table 33 : Novartis: Oncology Pharmaceutical Products Portfolio
Table 34 : Novartis: Oncology Pharmaceutical Revenue, 2018-2020
Table 35 : Pfizer Inc.: Oncology Pharmaceutical Products Portfolio
Table 36 : Pfizer Inc.: Marketed Products
Table 37 : Pfizer Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 38 : Sanofi: Oncology Pharmaceutical Products Portfolio
Table 39 : Sanofi: Oncology Pharmaceutical Revenue, 2018-2020
List of Figures
Summary Figure : Global Market for DNA Repair Drugs, by Type, 2020-2026
Figure 1 : Pathway of Cellular DNA Damage and Repair
Figure 2 : Chemical Structural of DNA Nucleotides
Figure 3 : Direct Repair of Thymine Dimers
Figure 4 : Repair of O6 - Methylguanine
Figure 5 : Short-Patch and Long-Patch BER Pathways
Figure 6 : Mechanism of NHEJ Repair of Double-Strand Breaks in DNA
Figure 7 : Characteristics-Based Excision Repair, Nucleotide Excision Repair and Mismatch Repair
Figure 8 : DNA Double Stand Base Repair Pathway
Figure 9 : Environmental Gear Selection
Figure 10 : Global Market for DNA Repair Drugs, by Type, 2020-2026
Figure 11 : Structure Schematic of PARP Molecule
Figure 12 : Interaction Between PARP and HR
Figure 13 : Chemical Structure Formula of PARP Inhibitors
Figure 14 : Global Market for DNA Repair Drugs, by Application, 2020-2026
Figure 15 : Incidence, Mortality and Prevalence of Ovarian Cancer
Figure 16 : Ovarian Cancer by Region and Gender
Figure 17 : Incidence, Mortality and Prevalence of Breast Cancer
Figure 18 : Breast Cancer, by Region and Gender
Figure 19 : Global Market Shares for DNA Repair Drugs, by Region, 2020
Figure 20 : North American Market Shares for DNA Repair Drugs, by Country, 2020
Figure 21 : European Market Shares for DNA Repair Drugs, by Country, 2020
Figure 22 : Asia-Pacific Market Shares for DNA Repair Drugs, by Country, 2020
Figure 23 : R&D Intensities for Publicly Traded U.S. Companies
Figure 24 : Annual Approvals of New Drugs by FDA
Figure 25 : New Drug Approvals
Figure 26 : U.S. Retail Drug Spending by Therapeutic Area
Figure 27 : BARDA Funding for COVID-19 Vaccine
